BR
Brooks Laboratories Ltd (BROOKS)
₹67.20
Mkt cap
₹200 Cr
P/E ratio
69.10
P/B
1.03
Div yield
0.00%
ROE
4.68%
ROCE
5.04%
EPS (TTM)
₹0.97
Book value
₹65
52W range
36–109
Sector
Healthcare
Price history
Previous close
Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment [1]
NSE BROOKSBSE 533543
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthLow
TechnicalsNeutral
52-week range
−38.18% from high₹67
₹36+85.12% from low₹109
Current
₹67.20
Prev close
₹67.30
Day
−0.15%
Price performance
1D
−0.39%
1W
+4.72%
1M
+9.74%
3M
+11.18%
6M
+30.99%
1Y
−37.32%
YTD
−13.02%
Financials
Revenue, profit & margin
P/E ratio
69.1×
BROOKS is 107% above the sector median of 33.4×
BROOKS69.1×
Sector median33.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026NSE | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15.70 | 24.32 | 21.75 | 17.72 | 17.93 | 20.79 | 20.52 | 23.32 | 25.51 | 23.45 | 16.57 | 20.21 | 22.96 | 19 | |
| YoY Sales growth | -8.29% | +34.51% | +42.16% | +40.52% | +14.20% | -14.51% | -5.66% | +31.60% | +42.28% | +12.79% | -19.25% | -13.34% | -10.00% | — | |
| Expenses | 19.61 | 25.42 | 25.12 | 27.25 | 19.85 | 24.20 | 22.02 | 24.58 | 22.38 | 20.93 | 15.84 | 19.53 | 24.30 | 19 | |
| Operating Profit | -3.91 | -1.10 | -3.37 | -9.53 | -1.92 | -3.41 | -1.50 | -1.26 | 3.13 | 2.52 | 0.73 | 0.68 | -1.34 | 0 | |
| OPM % | -24.90% | -4.52% | -15.49% | -53.78% | -10.71% | -16.40% | -7.31% | -5.40% | 12.27% | 10.75% | 4.41% | 3.36% | -5.84% | 2% | |
| Other Income | 0.05 | 0.09 | 0.16 | 0.65 | 0.07 | 0.20 | 0.03 | 0.62 | 7.15 | 6.13 | 5.32 | 1.35 | 0.18 | 73 | |
| Interest | 0.17 | 0.19 | 0.21 | 0.27 | 0.16 | 0.32 | 0.28 | 0.26 | 0.30 | 0.28 | 0.16 | 0.09 | 0.21 | 0 | |
| Depreciation | 0.44 | 0.44 | 0.43 | 0.46 | 0.40 | 0.43 | 0.38 | 0.39 | 0.39 | 0.39 | 0.39 | 0.41 | 0.42 | 0 | |
| Profit before tax | -4.47 | -1.64 | -3.85 | -9.61 | -2.41 | -3.96 | -2.13 | -1.29 | 9.59 | 7.98 | 5.50 | 1.53 | -1.79 | 73 | |
| Tax % | 0.00% | 0.00% | 0.78% | 0.00% | 0.00% | 0.00% | 0.00% | 13.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 7% | |
| Net Profit | -4.47 | -1.64 | -3.88 | -9.61 | -2.41 | -3.96 | -2.13 | -1.46 | 9.58 | 7.98 | 5.50 | 1.52 | -1.79 | 68 | |
| EPS in Rs | -1.80 | -0.62 | -1.48 | -3.66 | -0.92 | -1.51 | -0.81 | -0.50 | 3.25 | 2.71 | 1.87 | 0.52 | -0.61 | 22.95 | |
| Raw PDF | — |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202652.62%Promoter
Promoters52.62%
FIIs0.04%0.04
DIIs10.50%0.12
Public36.84%0.16
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,870.00 | 36.46 | 4,48,676 | 0.86% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,150.00 | 86.62 | 2,95,997 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,668.80 | 81.80 | 1,77,586 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,338.00 | 94.28 | 1,26,325 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,204.20 | 26.51 | 1,20,119 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,388.00 | 41.41 | 1,15,936 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,388.00 | 36.11 | 1,12,135 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Brooks Lab. | ₹67.80 | 69.11 | 200 | 0.00% | 70 | −75.00% | 19 | −17.91% | 5.04% |
| Median: 160 Co. | ₹445.73 | 33.35 | 2,016 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Credit Rating 12 Nov - CARE upgraded Brooks Laboratories’ ratings; received ₹106.33 crore from stake sale, becoming net debt free.Announcement under Regulation 30 (LODR)-Newspaper Publication 9 Nov - Brooks Laboratories Limited has informed about copy of Newspaper Publication.Financial Results For The Quarter And Half Year Ended September 30, 2026 7 NovBoard Meeting Outcome for Board Meeting Outcome For Financial Results For The Quarter And Half Year Ended September 30, 2026 7 Nov - Board approved Q2/H1 FY27 results; Brooks sold 11.48% stake in BSL for Rs 7,473.60 lakh, booking Rs 7,470 lakh gain.Board Meeting Outcome for Board Meeting Outcome For Financial Results For The Quarter And Half Year Ended September 30, 2026 7 Nov - Board approved Q2 FY26 results; partial divestment of Brooks Steriscience stake for Rs7,473.60 lakh.






